Physician profile

Michael David Kreines

Gastroenterology (Internal Medicine) · Cincinnati, OH

NPI 1194714907

$1,244.01

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

See the full distribution for Gastroenterology (Internal Medicine)

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $328.84 2019-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $177.29 2019-2022
Pfizer INC. $152.42 2019-2021
Takeda Pharmaceuticals U.S.A., INC. $135.57 2019-2021
Nestle Healthcare Nutrition INC. $67.93 2021
Gilead Sciences, INC. $60.00 2019-2020
Celgene Corporation $55.24 2021-2022
Amgen INC. $53.10 2020-2022
Qol Medical, LLC $50.33 2019-2021
Endo Pharmaceuticals INC. $29.79 2019
Merck Sharp & Dohme LLC $27.56 2019-2020
Ucb, INC. $26.79 2019
Shire North American Group INC $17.76 2019
Daiichi Sankyo INC. $13.54 2019
Janssen Biotech, INC. $12.61 2021
Show all 18 companies
CompanyGeneral paymentsYearsTop products
Allergan, INC. $12.13 2020
Ironwood Pharmaceuticals, INC $11.78 2021
Boston Scientific Corporation $11.33 2020

5 companies reported research payments only; those appear in the research section below.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael David Kreines

$1,244.01

in general payments reported 2019-2025

Years
2019-2022
Top company
Abbvie INC.

https://glasscript.com/doctor/8968/michael-david-kreines

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.